<DOC>
	<DOCNO>NCT01391260</DOCNO>
	<brief_summary>The purpose study access effect safety radiotherapy combine whth Iressa patient locally advance non-small cell lung cancer harbor active EGFR mutation .</brief_summary>
	<brief_title>Radiotherapy Combined With Iressa EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Worldwide half million new case lung cancer diagnose annually . About 80 % tumours non-small cell histological type . Surgery treatment choice , 20 % tumour suitable potentially curative resection . Concurrent chemoradiotherapy standard treatment locally advance NSCLC . When Iressa use first-line treatment advance NSCLC EGFR mutation positive , 12-month rate progression-free survival 24.9 % . Therefore , speculate EGFR mutation patient locally advanced NSCLC , Gefitinib combine radiotherapy may better chemoradiotherapy . We design study access effect safety radiotherapy combine whth Iressa patient locally advance non-small cell lung cancer harbor active EGFR mutation .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically confirm diagnosis nonsquamous NSCLC ; Stage ⅢAⅢB ( suitable surgery ) stage Ⅳ ( singlesite single transfer ) ; Untreated patient , complete ≤ 2 cycle firstline chemotherapy ( chemotherapy regimen : paclitaxel , docetaxel + cisplatin ) within previous month ; Patients tumor EGFR mutation positive ( exon 19 deletion mutation exon 21 L858R substitution mutation ) ; Patients must inform investigational nature study must sign informed consent form ; Presence least one measurable/evaluable accord RECIST criterion . ECOG performance Status 02 ; Patients must life expectancy &gt; 12 week ; Patients laboratory value follow : WBC＞4.0 x 109/L ; ANC≥1.5 x 109/L ; PLT≥100 x 109/L ; HGB≥10 g/dL ; CR≤1.5 x ULN ; TBIL＜1.5 x ULN ; AST ALT≤1.5 x ULN ; LDH≤1.5 x ULN ; AKP≤5 x ULN ; FEV 1≥1.0L ＞50 % Corresponding normal value ; Patient candidate standard platinumbased chemotherapy ; Patients must nonpregnant nonlactating.Patients childbearing potential must implement effective method contraception study . All female Patients , except postmenopausal surgically sterilize , must negative prestudy serum urine pregnancy test . Any evidence clinically active interstitial lung disease ; Diagnosis malignancy last 5 year , except situ carcinoma cervix uterine squamous cell carcinoma skin； Pregnancy lactating； Serious concomitant infection ; MI within precede 6 month symptomatic heart disease , include unstable angina , congestive heart failure uncontrolled arrhythmia ; As judged investigator , evidence severe uncontrolled systemic disease ( eg , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) ; Patients suitable participate trial accord researcher .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Locally Advanced NSCLC</keyword>
	<keyword>EGFR Mutation Positive</keyword>
	<keyword>Radiotherapy combine Gefitinib</keyword>
</DOC>